Results 251 to 260 of about 2,978,826 (285)

Controlling extensively drug-resistant tuberculosis

The Lancet, 2007
Recent successes in the fight against tuberculosis rely on short-course chemotherapy with our two most powerful drugs isoniazid and rifampicin. Unfortunately not only do hundreds of thousands of people or more still die every year of curable tuberculosis1 but inadequate treatment has also contributed to the origination of strains of tuberculosis ...
Travis C, Porco, Wayne M, Getz
openaire   +2 more sources

Multidrug and extensively drug-resistant tuberculosis

Médecine et Maladies Infectieuses, 2017
The emergence of drug-resistant tuberculosis (TB) compromises global tuberculosis control. The incidence of multidrug-resistant strains (MDR) defined as resistant to the two main antituberculosis drugs, rifampicin and isoniazid, was raised in the 1990s.
Maitre, Thomas, Aubry, A., Jarlier, V., Robert, J., Veziris, Nicolas, Bernard, C., Sougakoff, W., Brossier, F., Cambau, E., Mougari, F., Raskine, L.   +10 more
openaire   +4 more sources

Delamanid for Extensively Drug-Resistant Tuberculosis

New England Journal of Medicine, 2015
Therapeutic options for extensively drug-resistant tuberculosis infection are limited. In this post-hoc analysis, a new drug, delamanid, shows some activity in the treatment of XDR-TB.
Rajesh, Gupta, Lawrence J, Geiter, Charles D, Wells, Mengqui, Gao, Andra, Cirule, Heping, Xiao   +5 more
openaire   +2 more sources

Drug-resistant and extensively drug-resistant tuberculosis in southern Africa

Current Opinion in Pulmonary Medicine, 2010
Drug-resistant tuberculosis (TB) is of increasing global concern. One of the hardest hit regions is southern Africa. This study focuses on a concise update on recently published developments in the field.There is mounting evidence from high-coprevalence areas that the TB and HIV pandemics must be viewed as an entity and tackled together.
openaire   +3 more sources

Predictors of Extensively Drug-Resistant Pulmonary Tuberculosis

Annals of Internal Medicine, 2009
About 40 000 cases of extensively drug-resistant tuberculosis emerge worldwide annually, but the predictors of extensive drug resistance are unclear.To identify risk factors for extensively drug-resistant tuberculosis and multidrug-resistant but non-extensively drug-resistant tuberculosis in patients with culture-confirmed pulmonary tuberculosis.Cross ...
Kai, Kliiman, Alan, Altraja
openaire   +2 more sources

Linezolid in the treatment of extensively drug-resistant tuberculosis

Infection, 2014
To investigate the linezolid (LZD) treatment outcome and correlation between in vitro susceptibility to LZD and clinical outcome.We retrospectively reviewed records of tuberculosis (TB) patients who received treatment with linezolid between March 2012 and February 2013.A total of 43 extensively drug-resistant (XDR) TB patients identified by drug ...
L, Zhang, Y, Pang, X, Yu, Y, Wang, M, Gao, H, Huang, Y, Zhao   +6 more
openaire   +2 more sources

Extensively Drug-Resistant Tuberculosis

2014
It has been many years since a single agent was recommended for treatment of active tuberculosis (TB). Despite this, there is strong evidence that multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are present in all regions of the world, and there is also evidence that the incidence of drug-resistant forms of TB is increasing ...
openaire   +1 more source

Treatment of extensively drug-resistant tuberculosis

The Lancet, 2009
Deepak, Aggarwal, Prasanta R, Mohapatra, Ashok K, Janmeja   +2 more
openaire   +2 more sources

Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis

Journal of Infection, 2023
Giovanni Sotgiu, Troels Lillebaek, Christoph Lange   +2 more
exaly  

Linezolid for Extensively Drug-Resistant Tuberculosis

New England Journal of Medicine, 2013
Ernesto, Jaramillo, Karin, Weyer, Mario, Raviglione   +2 more
openaire   +4 more sources